Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan Extension in Inoperable CTEPH
NCT01894022Phase 3Terminated
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of ambrisentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by GSK. Started Jan 2014; status: terminated.
02
Drugs
ambrisentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT01894022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01894022.